Role of Calcium Binding Protein S100A12 in Diagnosis and Prognosis of Kawasaki Disease

Study Overview
=================
Brief Summary
-----------------
Recent studies showed that the value of c100A12 increased in children with Kawasaki disease, and decreased rapidly after treatment with gamma globulin. In kawasaki disease with coronary artery dilatation, S100A12 levels are elevated in the acute phase of Kawasaki disease and continue for some time in the convalescence phase before gradually decreasing. However, the number of patients included in previous studies was small and the follow-up time was short. In this study, 100 children with Kawasaki disease who were admitted to Wuhan Children's Hospital, Jingzhou First People's Hospital and Renhe Hospital affiliated to China Three Gorges University from December 2021 to December 2023 were selected as the research objects, and 100 children with healthy physical examination were selected as the control group during the same period. To investigate whether S100A12 increased significantly in the acute phase of Kawasaki disease compared with a healthy control group. To study whether S100A12 value increased rather than decreased in kawasaki disease that did not respond to gamma globulin treatment after gamma globulin treatment. At the same time, to study whether the increase of S100A12 in kawasaki disease convalescence indicates coronary aneurysm.

Detailed Description
-----------------
S100A12 was determined using the ELISA kit and according to the instructions.

Official Title
-----------------
Role of Calcium Binding Protein S100A12 in Diagnosis and Prognosis of Kawasaki Disease

Conditions
-----------------
Diagnoses Disease

Intervention / Treatment
-----------------
* Diagnostic Test: S100A12


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ▪Diagnostic criteria of Kawasaki disease revised by the American Heart Association in 2017 Exclusion Criteria: Scarlet fever Drug allergy syndrome Stevens-Johnson syndrome Toxic shock syndrome Adenovirus infection Epstein-Barr(EB) virus infection
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Kawasaki disease<br>All children with Kawasaki disease met the diagnostic criteria for Kawasaki disease revised by the American Heart Association in 2017. | Diagnostic Test: S100A12<br>* The early dynamic detection of S100A12 was used to determine whether it was an auxiliary diagnostic index for Kawasaki disease<br>|
| Healthy controls<br>Healthy control group were healthy children who underwent outpatient physical examination. | Diagnostic Test: S100A12<br>* The early dynamic detection of S100A12 was used to determine whether it was an auxiliary diagnostic index for Kawasaki disease<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| S100A12 | S100A12 was increased in children with Kawasaki disease and decreased after gamma globulin treatment | From date of randomization until the date of first documented progression, whichever came first, assessed up to 18 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CRP | Measure the CRP value | From date of randomization until the date of first documented progression, whichever came first, assessed up to 18 months |